epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-405, Phase III. Recruiting

A rare inherited neuromuscular disorder (genetically confirmed)

TSR-405 against placebo in an inherited neuromuscular disorder. Sponsor: Tailspin Rare Diseases (fictional), Rare disease.

QTLs at a glance

Data to September 30th 2026. Each measure links to its chart below.

Missing primary endpoint data

Too early

Too early Fewer than 50 patients

Lost to follow-up or withdrew consent

Too early

Too early Fewer than 50 patients

Stopped study treatment early

Too early

Too early Fewer than 50 patients

Ineligible patients randomised

Too early

Too early Fewer than 50 patients

Will the result hold?

Quality tolerance limits (acceptable ranges, in ICH E6(R3)), most important first. Priority is how likely this study's design makes a breach, times how strongly the evidence links the measure to a reliable result. Each has an early-warning line, a limit and a critical line where the study's power would fall to the escalation level.

RankQTLLikelihoodImpactWhy it is likely hereWatched at sites byWarningLimitCritical
1Missing primary endpoint dataEvidence grade A23
  • Follow-up burden and duration (EB-17)From the design: How heavy is the visit and procedure schedule? Heavier than typical
  • Procedural and visit burden (visits, blood draws, questionnaires) (PD-03)From the design: How heavy is the visit and procedure schedule? Heavier than typical
10.1%15%33.2%
2Lost to follow-up or withdrew consentEvidence grade A23
  • Follow-up burden and duration (EB-17)From the design: How heavy is the visit and procedure schedule? Heavier than typical
  • Procedural and visit burden (visits, blood draws, questionnaires) (PD-03)From the design: How heavy is the visit and procedure schedule? Heavier than typical
4.5%6%24.3%
3Stopped study treatment earlyEvidence grade B32
  • Placebo or no-added-treatment control arm (PD-05)From the design: What does the control arm receive? Placebo or no added treatment
  • Procedural and visit burden (visits, blood draws, questionnaires) (PD-03)From the design: How heavy is the visit and procedure schedule? Heavier than typical
12.5%15%22%
4Ineligible patients randomisedEvidence grade B12None of its drivers applies to this design4%5%14.5%

Missing primary endpoint data

Too early to judge% of patients; benchmark median 7.9%

Show data
Missing primary endpoint data: running rate by month
MonthPatientsRate
Mar 202610%
Jun 202630%
Sep 202640%
Oct 202650%

The acceptable range is the drop-out the study's power calculation allowed for (planner parameters, D24); the early-warning line sits at two-thirds of it

Lost to follow-up or withdrew consent

Too early to judge% of patients; benchmark median 3.7%

Show data
Lost to follow-up or withdrew consent: running rate by month
MonthPatientsRate
Sep 202510%
Dec 202530%
Mar 202640%
Jun 202650%
Sep 202670%
Oct 202670%

epiClinical assumption: above the combined benchmark median of 3.7% and in line with published case studies that set limits around 4% for unknown survival status

Stopped study treatment early

Too early to judge% of patients; benchmark median 10.7%

Show data
Stopped study treatment early: running rate by month
MonthPatientsRate
Sep 202510%
Dec 202530%
Mar 202640%
Jun 202650%
Sep 202670%
Oct 202670%

epiClinical assumption: above the Phase III benchmark of 11.5%; a breach dilutes the treatment effect and reduces power

Ineligible patients randomised

Too early to judge% of patients; benchmark median 3.2%

Show data
Ineligible patients randomised: running rate by month
MonthPatientsRate
Sep 202510%
Dec 202530%
Mar 202640%
Jun 202650%
Sep 202670%
Oct 202670%

epiClinical assumption: above the 3.2% median; eligibility errors were reported in 39% of 82 trials

Patients needed before a QTL is judged: 50. epiClinical assumption: QTL rates are unstable with few patients, and many early breaches in vendor data were noise (review note 01).

Breaches and decisions

No QTL in EPI-405 has passed its early-warning line, so nothing needs evaluating.

Critical lines assume each study was designed for 80% power at a two-sided 5% level, and mark where power would fall to 70%. Missing outcome data can bias a result well before it costs power, so its limit, not its critical line, is the one to act on.